Thymosin Alpha-1
Also known as: Tα1, Thymalfasin, Zadaxin
The immune system optimizer — FDA-studied thymic peptide for immune regulation and viral defense.
Molecular structure image coming soon
Research use only in the US. Approved as Zadaxin in 35+ countries. Consult immunologist for complex immune conditions.
Overview
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide produced in the thymus gland. It plays a central role in immune regulation — activating T-cells, natural killer (NK) cells, and dendritic cells. It has been approved in over 35 countries under the brand name Zadaxin for treatment of hepatitis B, hepatitis C, and as an adjuvant cancer therapy. It is widely used in functional medicine and longevity protocols.
Mechanism of Action
Thymosin Alpha-1 acts on toll-like receptors (TLR-9) and stimulates the differentiation and proliferation of T-lymphocytes. It enhances NK cell activity, promotes Th1 cytokine responses (interferon-gamma, IL-2), and modulates inflammatory pathways to promote immune homeostasis rather than simple stimulation.
Use Cases
- ✓Immune system modulation and optimization
- ✓Chronic viral infections (hepatitis B, C, EBV, Lyme)
- ✓Cancer immunotherapy adjuvant
- ✓Post-COVID immune dysregulation
- ✓Chronic fatigue syndrome and MECFS
- ✓Autoimmune conditions (immune regulation)
- ✓Mold/mycotoxin illness
Research Summary
Thymosin Alpha-1 has been studied in over 50 randomized controlled trials. FDA Orphan Drug designation was granted for DiGeorge syndrome. Approved in 35+ countries for hepatitis and cancer. A 2020 study in China demonstrated improved survival in COVID-19 critically ill patients treated with Thymosin Alpha-1.
Typical Dosing
1.6 mg subcutaneous injection 1–2x weekly. Some protocols use 900 mcg 3x weekly for immune support.
Administration
Research Chemical
Research use only in the US. Approved as Zadaxin in 35+ countries. Consult immunologist for complex immune conditions.
